|
India's CDSCO has approved the first dengue vaccine, Qdenga, for individuals aged 4 to 60 after rigorous evaluation. |
|
0
|
18
|
|
today
|
|
India has approved QDENGA, its first dengue vaccine. A pulmonary specialist explains who should get vaccinated, who should avoid it, why two doses are needed, and why mosquito control remains essential even after vaccination. |
|
0
|
23
|
|
today
|
|
India has taken a major step in the fight against dengue after the Central Drugs Standard Control Organisation (CDSCO) approved Takeda's QDENGA (TAK-003), ma |
|
0
|
21
|
|
1 day
|
|
India approves Takeda's QDENGA dengue vaccine for ages 4-60, offering protection against all virus serotypes without prior screening. |
|
0
|
18
|
|
1 day
|
|
One of its key advantages of the QDENGA vaccine is that it protects against all four dengue strains and can be given regardless of whether a person has previously had dengue. |
|
0
|
16
|
|
1 day
|
|
India approves QDENGA, its first dengue vaccine, offering protection against all four dengue virus strains for people aged 4 to 60 years. , Health, Times Now |
|
0
|
10
|
|
1 day
|
|
India has approved its first dengue vaccine, QDENGA, for people aged 4 to 60 years. Know who can receive it, how the two-dose vaccine works, why it does not require pre-vaccination screening and what the approval means for dengue prevention in India. |
|
0
|
12
|
|
1 day
|
